Lixte Biotechnology (NASDAQ:LIXT) Stock Price Up 0.9% – Here’s Why

Shares of Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) were up 0.9% on Wednesday . The stock traded as high as $1.28 and last traded at $1.19. Approximately 6,424 shares traded hands during trading, a decline of 97% from the average daily volume of 185,853 shares. The stock had previously closed at $1.18.

Lixte Biotechnology Stock Up 0.9 %

The stock has a fifty day moving average price of $1.22 and a two-hundred day moving average price of $1.73. The company has a market cap of $3.75 million, a price-to-earnings ratio of -0.69 and a beta of 0.40.

Lixte Biotechnology (NASDAQ:LIXT) last posted its quarterly earnings data on Monday, March 24th. The company reported ($0.27) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Lixte Biotechnology

A number of hedge funds have recently added to or reduced their stakes in the stock. Atlas Legacy Advisors LLC bought a new position in shares of Lixte Biotechnology in the fourth quarter worth $26,000. FNY Investment Advisers LLC increased its holdings in Lixte Biotechnology by 172.8% in the 1st quarter. FNY Investment Advisers LLC now owns 107,000 shares of the company’s stock valued at $129,000 after buying an additional 67,781 shares during the period. Finally, TIAA Trust National Association bought a new position in Lixte Biotechnology in the 4th quarter valued at about $207,000. Institutional investors own 5.10% of the company’s stock.

About Lixte Biotechnology

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.